Johnson & Johnson (JNJ/NYSE): general analysis

Since the beginning of 2018, Johnson & Johnson stocks have lost more than 5.5%. The issuer is under pressure due to the decrease in sales of key medicines during last quarters and the growing competition with Pfizer.